Loading...
  • patients
  • No information is available on the relationship of age to the effects of hydralazine in geriatric patients. (mayoclinic.org)
  • A total of 143 patients (alpha 0.5, power 0.8)with metastatic, persistent or recurrent cervical cancer without previous systemic treatment will be randomized to cisplatin topotecan + placebo or cisplatin topotecan hydralazine valproate for 6 courses every 3 weeks. (clinicaltrials.gov)
  • heart
  • Hydralazine works by relaxing the blood vessels and increasing the supply of blood and oxygen to the heart while reducing its workload. (mayoclinic.org)
  • The temporal discordance of the changes of both heart rate and plasma norepinephrine relative to the reduction in blood pressure and the significant linear correlation between the increases in heart rate and plasma norepinephrine concentration suggest that continued activation of the peripheral sympathetic nervous system contributes to the persistent tachycardia seen after the administration of hydralazine. (ahajournals.org)
  • increase
  • Hydralazine may also increase plasma renin concentration, resulting in fluid retention. (wikipedia.org)
  • Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo. (clinicaltrials.gov)
  • therapy
  • To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival. (clinicaltrials.gov)
  • Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer. (clinicaltrials.gov)